LiverLearning®: 2020 Webinar: Novel Models for HCV Care Delivery

In order to achieve the World Health Organization's goal of treating at least 80% of identified HCV-infected patients, novel models of HCV care delivery should be implemented. This webinar will address telemedicine and digital telemedicine with respect to HCV care and will attempt to demonstrate improved models of linkage to care in both urban and exurban settings.John D. Scott John Scott, MD, MSc is a Professor of Medicine (Division of Allergy and Infectious Diseases) and Medical Director of Digital Health at the University of Washington.

A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis

Sonia Alonso López, María Luisa Manzano, Francisco Gea, María Luisa Gutiérrez, Adriana Maria Ahumada, María José Devesa, Antonio Olveira, Benjamin Arturo Polo, Laura Márquez, Inmaculada Fernández, Juan Carlos Ruiz Cobo, Laura Rayón, Daniel Riado, Sonia Izquierdo, Clara Usón, Yolanda Real, Diego Rincón, Conrado M. Fernández‐Rodríguez, Rafael Bañares – 6 October 2020

The Predictive Role of Model for End‐Stage Liver Disease–Lactate and Lactate Clearance for In‐Hospital Mortality Among a National Cirrhosis Cohort

Nadim Mahmud, Sumeet K. Asrani, David E. Kaplan, Gerald O. Ogola, Tamar H. Taddei, Patrick S. Kamath, Marina Serper – 6 October 2020 – The burden of cirrhosis hospitalizations is increasing. The admission Model for End‐Stage Liver Disease–lactate (MELD‐lactate) was recently demonstrated to be a superior predictor of in‐hospital mortality compared with MELD in limited cohorts. We identified specific classes of hospitalizations where MELD‐lactate may be especially useful and evaluated the predictive role of lactate clearance.

Subscribe to